Dechra Pharmaceuticals (BATS-CHIXE:DPHL) - Cotización, noticias y análisis

Resumen de acción DPHL

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Saber más

Análisis fundamental de DPHL
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	4/6
Rendimiento pasado	0/6
Salud financiera	1/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 62.48%

Análisis de riesgos

Los pagos de intereses no están bien cubiertos por los beneficios

Competidores de Dechra Pharmaceuticals PLC

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

HUTCHMED (China)

AIM:HCM

UK£2.4b

Indivior

LSE:INDV

UK£1.1b

GSK

LSE:GSK

UK£54.8b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Dechra Pharmaceuticals
Precios históricos de las acciones
Precio actual de la acción	UK£38.70
Máximo en las últimas 52 semanas	UK£38.84
Mínimo de 52 semanas	UK£24.74
Beta	0.78
1Cambio en 1 mes	0.55%
Variación en 3 meses	2.27%
Cambio de 1 año	35.79%
3Variación en 3 años	5.91%
Variación en 5 años	63.71%
Variación desde la OPV	744.98%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	DPHL	GB Pharmaceuticals	Mercado GB
7D	0.2%	4.5%	2.2%
1Y	35.8%	0.7%	8.0%

Rentabilidad vs. Industria: DPHL superó a la industria UK Pharmaceuticals, que obtuvo un rendimiento del 0.7% el año pasado.

Rentabilidad vs. Mercado: DPHL superó al mercado UK, que obtuvo un rendimiento del 8% el año pasado.

Volatilidad de los precios

Is DPHL's price volatile compared to industry and market?
DPHL volatility
DPHL Average Weekly Movement	0.5%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: DPHL no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de DPHL ha disminuido de 6% a 1% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1997	2,457	Ian Page	www.dechra.com

Resumen de fundamentos de Dechra Pharmaceuticals PLC

¿Cómo se comparan los beneficios e ingresos de Dechra Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de DPHL
Capitalización bursátil	UK£4.40b
Beneficios(TTM)	-UK£27.90m
Ingresos (TTM)	UK£761.50m

5.8x

Ratio precio-ventas (PS)

-157.8x

Ratio precio-beneficio (PE)

¿Está DPHL sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de DPHL
Ingresos	UK£761.50m
Coste de los ingresos	UK£331.90m
Beneficio bruto	UK£429.60m
Otros gastos	UK£457.50m
Beneficios	-UK£27.90m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.24
Margen bruto	56.42%
Margen de beneficio neto	-3.66%
Ratio deuda/patrimonio	64.6%

¿Cómo se ha desempeñado DPHL a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción DPHL

Recompensas

Análisis de riesgos

Competidores de Dechra Pharmaceuticals PLC

LSE:HIK

UK£4.3b

AIM:HCM

UK£2.4b

LSE:INDV

UK£1.1b

LSE:GSK

UK£54.8b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Dechra Pharmaceuticals PLC

5.8x

-157.8x

Beneficios e Ingresos